Lipoprotein (a): implication in atherothrombosis.
Substantial experimental evidence now implicates lipoprotein (a) as an independent risk factor for premature cardiovascular disease. Both plasma Lp(a) levels and apo(a) phenotype are strong predictors of risk for ischaemic heart disease. The accumulation of apo(a) in vascular wall tissue and in atherosclerotic plaques and the potential inhibition of fibrinolysis by Lp(a) underlie the enhanced risk of premature cardiovascular disease associated with this cholesterol-rich particle. Recent studies of the capacity of purified Lp(a) isoforms to inhibit fibrinolysis in an in vitro system have revealed that small isoforms of Lp(a) (< or = 500 kDa) are efficient inhibitors of plasminogen activation and bind with high affinity to fibrin. Conversely, large isoforms exert little or no inhibitory effect in this system (> 500 kDa). These data suggest that the potential, high affinity interaction of Lp(a) particles containing small isoforms with fibrin introduces a new, third dimension to the atherothrombotic risk associated with these cholesterol-rich particles.
INSERM Unité 321, Unité de Recherche sur les Lipoprotéines et l'Athérogénèse, Hôpital de la Pitié, Paris, France.
M J
MJ
Chapman
T
T
Huby
F
F
Nigon
J
J
Thillet
D001054:Apolipoproteins A / Q000097:blood / Q000502:physiology*; D003327:Coronary Disease / Q000097:blood / Q000503:physiopathology*; D003328:Coronary Thrombosis / Q000097:blood / Q000503:physiopathology; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood / Q000502:physiology*; D012307:Risk Factors
D001054:Apolipoproteins A; D017270:Lipoprotein(a)